Intravenous immunoglobulin-based immunotherapy: an arsenal of possibilities for patients and science.
The use of intravenous immunoglobulin (IVIG) concentrated from pooled healthy donors' plasma has gained increasing popularity. IVIG therapy has become important as a replacement therapy in primary and acquired humoral immunodeficiencies, and it has been extended to autoimmune, neurodegenerative and inflammatory conditions and transplantation therapy. Recurrent pregnancy failure and cancer are rather new platforms, where IVIG has shown its beneficial effects. This manuscript is focused on these two off-labelled usages. The immunomodulatory mechanisms of IVIG therapy appear as a coordinated orchestration of different functions, resulting in a synergistic effect. Treatment monitoring and detailed molecular analyses reveal how such treatments may interfere with disease pathogenesis. These finding may foster the development of novel therapeutic and/or preventive strategies. Studying this field with bidirectional bench-to-bedside and bedside-to-bench approaches fit well into 'the two-way road' paradigm of translational medicine.
Kotlan
Beatrix
B
Center of Surgical & Molecular Tumorpathology National Institute of Oncology, Rath Gy street 7-9, Budapest 1122, Hungary. kotlanb@netscape.net
Stroncek
David F
DF
Marincola
Francesco M
FM
D000026:Abortion, Habitual / Q000188:drug therapy* / Q000276:immunology; D000818:Animals; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D056747:Immunomodulation; D007167:Immunotherapy; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011247:Pregnancy; D057170:Translational Research, Biomedical
D016756:Immunoglobulins, Intravenous